References
- Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230–238
- Balamurugan AN, Bottino R, Giannoukakis N, et al. Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes. Pancreas 2006; 32(3)231–243
- Davalli AM, Scaglia L, Zangen DH, et al. Vulnerability of islets in the immediate posttransplantation period: Dynamic changes in structure and function. Diabetes 1996; 45: 1161–1167
- Mayes JT, Dennis VW, Hoogwerf BJ. Pancreas transplantation in type 1 diabetes: Hope vs. reality. Cleve Clin J Med 2000; 67: 281–286
- Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus: the role of immunosuppression. Drug Saf 1997; 16: 242–257
- Fenjves ES, Ochoa MS, Gay-Rabinstein C, et al. Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: Implications for islet transplantation. Cell Transplant 2004; 13(5)489–496
- Pearl-Yafe M, Yolcu ES, Yaniv I, et al. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays 2006; 28(2)211–222
- Sun H, Aitouche A, Salam A, et al. The role of Fas/FasL apoptotic pathway in the development of chronic rejection. Transplant Proc 1999; 31(1–2)1397–1398
- Martinez OM, Krams SM. Involvement of Fas–Fas ligand interactions in graft rejection. Int Rev Immunol 1999; 18(5–6)527–546
- Thorburn A. Death receptor-induced cell killing. Cell Signal 2004; 16(2)139–144
- Hill JM, Morisawa G, Kim T, et al. Identification of an expanded binding surface on the FADD death domain responsible for interaction with CD95/Fas. J Biol Chem 2004; 279(2)1474–1481
- Wen-Hui H, Holly J, Hong-Bing S. Activation of NF-kB by FADD. Casper, and caspase-8. J Biol Chem 2000; 275(15)10838–10844
- Holst HU, Dagnaes-Hansen F, Corydon TJ, et al. LDL receptor-GFP fusion proteins: New tools for the characterization of disease-causing mutations in the LDL receptor gene. Eur J Hum Genet 2001; 9: 815–822
- Hamaguchi K, Gaskins HR, Leiter EH. NIT-1, a pancreatic beta-cell line established from a transgenic NOD/LT mouse. Diabetes 1991; 40: 842–849
- Varlamov O, Fricker LD, Furrkawa H, et al. Beta-cell lines derived from transgenic Cpe[fata]/Cpe[fata] mice are defective in carboxypeptidase E and proinsulin processing. Endocrinology 1997; 138: 4883–4892
- Holstad M, Sandler S. Prolactin protects against diabetes induced by multiple low doses of streptozotocin in mice. J Endocrinol 1999; 163: 229–234
- Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738–743
- Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-la donors. Diabetes 1993; 42: 44–45
- Shimizu J, Kanagawa O, Unanue ER. Presentation of beta-cell antigens to CD4+ and CD8+ T cells of nonobese diabetic mice. J Immunol 1993; 151: 1723–1730
- Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39–43
- Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449–1456
- Nagata S. Apoptosis mediated by the Fas system. Prog Mol Subcell Biol 1996; 16: 87–103
- Cremestic AF, Paris H, Grassme NH, et al. Ceramide enables Fas to cap and kill. J Biol Chem 2001; 276: 23954–23961
- Abdelaziz A, Joan V, Shari T, et al. IL-1α, IL-1β, and IFN-γmarkβcells for Fas-dependent destruction by diabetogenic CD4+T lymphocytes. J Clin Invest 2000; 105: 459–468
- Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95) associated proteins form a death-inducing signaling complex (DISC) with the receptor. J EMBO 1995; 14: 5579–5588
- Decallonne B, van Etten E, Giulietti A, et al. Defect in activation-induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun 2003; 20(3)219–226
- Dharnidharka VR, Van Patten Y, Bahjat FR, et al. Fas stimulation results in selective islet infiltrate apoptosis in situ and reversal of diabetes. Ann NY Acad Sci 2002; 958: 160–162